Friday 6 November 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
114.36
5.60
+5.15%
Follow INSM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 5 | 5 |
| (249.28%) | (294.46%) | (87.22%) | (72.45%) | ||
| (59.53%) | (61.04%) | (38.20%) | (26.41%) | ||
ROIC |
0.00% | (1,659.95%) | (329.22%) | (247.55%) | |
Return on Tangible Assets |
(89.39%) | (87.36%) | (67.21%) | (49.71%) | |
Average Days of Receivables |
84.78 | 79.52 | 69.09 | 62.27 | |
Free Cash Flow per Share |
(4.86) | (4.28) | (3.72) | (2.87) | |
Free Cash Flow |
(967.57) | (921.63) | (807.67) | (627.57) | |
Capital Expenditures |
(32.56) | (25.97) | (28.75) | (31.95) | |
| Other line items | |||||
Cash ROIC |
(35.43%) | (37.01%) | (32.56%) | (25.77%) | |
Accounts Receivable Turnover |
6.29 | 7.24 | 8.42 | 9.37 | |
Accounts Payable Turnover |
0.33 | 0.51 | 0.51 | 0.48 | |
Inventory Turnover |
1.07 | 1.28 | 1.51 | 1.66 | |
Average Days of Payables |
1,354.03 | 863.18 | 831.80 | 884.59 | |
Days of Inventory on Hand |
392.11 | 325.41 | 276.12 | 252.42 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
127.15% | 101.03% | 75.67% | 62.14% | |
Selling, General and Administrative Expense of Revenue |
115.62% | 97.72% | 78.55% | 63.19% | |
Share Based Compensation of Revenue |
25.18% | 19.43% | 13.84% | 11.01% | |
Interest Coverage |
(14.88) | (14.00) | (10.34) | (6.93) | |
Operating CF/Net income |
0.73 | 0.76 | 0.89 | 0.98 | |
Depreciation/Fixed assets |
0.25 | 0.26 | 0.26 | 0.30 | |
Capex/Depreciation |
(1.28) | (0.97) | (1.02) | (0.98) | |
Revenue per Share |
3.05 | 3.80 | 5.23 | 6.95 | |
Operating CF per Share |
(4.70) | (4.16) | (3.58) | (2.72) | |
Capex per Share |
(0.16) | (0.12) | (0.13) | (0.15) | |
Capex to Sales |
0.05 | 0.03 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 2 Nov 2026